Savara Inc (SVRA) Stock Price, Quote & News

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 512 614 1848

Website: www.savarapharma.com

Address:

1717 Langhorne Newtown Road, Suite 300 One Summit Square, Langhorne, United States

BioGem May. 24 at 11:49 PM

$SVRA I continue to add shorts above $5 as the Q1 report was quite disastrous financially. Their losses are just surreal, and they are burning cash like no other. And, they haven't even built the sales team to launch yet. Imagine the huge dilution coming.

0 · Reply

BaronVonGrimm May. 20 at 10:37 PM

$SVRA will rest $11-$16

0 · Reply

Zeffanator2 May. 20 at 6:28 PM

$SVRA We will be just fine…..

2 · Reply

Spacemonkey1 May. 20 at 1:07 PM

$SVRA hard to argue this data doesn’t significantly reinforce likelihood of FDA approval. They love biomarkers and functional improvements. They got both.

0 · Reply

DARKP00L May. 20 at 12:55 PM

$SVRA 08:17 on May. 20 2026 Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference #tradeideas

0 · Reply

ckruel May. 19 at 8:31 PM

$SVRA https://finance.yahoo.com/sectors/healthcare/articles/savara-presented-long-term-efficacy-181500105.html

1 · Reply

biovaluable May. 19 at 2:13 PM

$SVRA major.amendants? The end?

0 · Reply

Richterscale May. 18 at 7:51 PM

$SVRA why is this getting hammered on? This is good news

2 · Reply

Richterscale May. 18 at 7:21 PM

$SVRA https://www.businesswire.com/news/home/20260518925976/en/

0 · Reply

Monkey7779192 May. 14 at 5:22 PM

$SVRA First time pdufa?

0 · Reply

Savara presents poster at ATS 2026 International Conference on IMPALA-2

May 20, 2026, 8:15 AM EDT - 4 days ago

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

ATS

May 19, 2026, 2:15 PM EDT - 5 days ago

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 19, 2026, 10:00 AM EDT - 5 days ago

Savara Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 18, 2026, 2:55 PM EDT - 6 days ago

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

2026-05-12T21:14:03.000Z - 12 days ago

Savara reports Q1 EPS (15c), consensus (14c)

May 12, 2026, 4:05 PM EDT - 12 days ago

Savara Reports First Quarter Financial Results and Provides Business Update

May 12, 2026, 4:00 PM EDT - 12 days ago

Savara Slides: Corporate presentation

May 12, 2026, 7:00 AM EDT - 12 days ago

Savara Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 12 days ago

Savara Earnings release: Q1 2026

May 11, 2026, 4:05 PM EDT - 13 days ago

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Apr 24, 2026, 8:00 AM EDT - 4 weeks ago

Savara Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 weeks ago

Savara Proxy statement: Proxy filing

2026-04-24T11:40:14.000Z - 4 weeks ago

Savara assumed with an Outperform at Oppenheimer

Apr 17, 2026, 4:05 PM EDT - 5 weeks ago

Savara Announces New Employment Inducement Grant

2026-04-15T20:10:15.000Z - 5 weeks ago

Savara says FDA extended review for Molgramostim BLA

Apr 15, 2026, 4:05 PM EDT - 5 weeks ago

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 14, 2026, 8:05 AM EDT - 5 weeks ago

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Apr 10, 2026, 8:00 AM EDT - 6 weeks ago

Savara Proxy statement: Proxy filing

2026-04-07T12:11:43.000Z - 6 weeks ago

Savara announces MHRA accepted submission of Molbreevi MAA

Apr 7, 2026, 8:05 AM EDT - 6 weeks ago

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 7, 2026, 7:00 AM EDT - 6 weeks ago

Savara Slides: Corporate presentation

Mar 30, 2026, 8:30 AM EDT - 7 weeks ago

Savara Slides: Corporate presentation

2026-03-30T12:19:50.000Z - 7 weeks ago

Savara announces EMA validation of MAA for MOLBREEVI

Mar 30, 2026, 8:05 AM EDT - 7 weeks ago

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

2026-03-13T12:50:39.000Z - 2 months ago

Savara reports Q4 EPS (13c), consensus (12c)

Mar 13, 2026, 8:05 AM EDT - 2 months ago

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Savara Earnings release: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Savara Annual report: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 2 months ago

Savara Slides: Corporate presentation

Mar 11, 2026, 10:10 AM EDT - 2 months ago

Savara Transcript: The Citizens Life Sciences Conference 2026

2026-03-06T21:15:14.000Z - 2 months ago

Savara announces receipt of Day 74 Letter from FDA

Mar 6, 2026, 4:05 PM EST - 2 months ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 6, 2026, 6:00 AM EST - 2 months ago

Savara Slides: Corporate presentation

Mar 4, 2026, 4:05 PM EST - 2 months ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Feb 25, 2026, 9:20 AM EST - 3 months ago

Savara Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-20T21:25:34.000Z - 3 months ago

Savara says FDA files BLA for Molbreevi

2026-02-20T21:20:31.000Z - 3 months ago

Savara announces BLA for Molbreevi filed for review by FDA

Feb 20, 2026, 4:15 PM EST - 3 months ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Feb 11, 2026, 12:30 PM EST - 3 months ago

Savara Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 3 months ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Jan 27, 2026, 8:05 AM EST - 4 months ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Jan 14, 2026, 8:15 PM EST - 4 months ago

Savara Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 4 months ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 7:00 AM EST - 4 months ago

Savara Slides: Corporate presentation

2025-12-23T11:11:14.000Z - 5 months ago

Savara price target raised to $10 from $8 at H.C. Wainwright

2025-12-22T13:42:07.000Z - 5 months ago

Savara resubmits Molbreevi BLA to the FDA

Dec 22, 2025, 8:30 AM EST - 5 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 17, 2025, 8:05 AM EST - 5 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

2025-12-11T13:16:21.000Z - 5 months ago

Savara announces EPO intention to grant Molbreevi patent application

Dec 11, 2025, 8:05 AM EST - 5 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 4, 2025, 10:00 AM EST - 6 months ago

Savara Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:30 PM EST - 6 months ago

Savara Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-02T19:25:21.000Z - 6 months ago

Savara rumor highlighted in Betaville blog

2025-12-02T13:36:08.000Z - 6 months ago

Savara issues patent for Molbreevi from European Patent Office

Dec 2, 2025, 8:05 AM EST - 6 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Nov 19, 2025, 7:00 AM EST - 6 months ago

Savara Transcript: Jefferies London Healthcare Conference 2025

2025-11-14T12:45:48.000Z - 6 months ago

Savara price target raised to $9 from $8 at Oppenheimer

2025-11-13T10:40:20.000Z - 6 months ago

Savara price target lowered to $10 from $11 at Citizens JMP

2025-11-12T21:16:13.000Z - 6 months ago

Savara reports Q3 EPS (14c), consensus (13c)

Nov 12, 2025, 4:05 PM EST - 6 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:00 PM EST - 6 months ago

Savara Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 6 months ago

Savara Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 6 months ago

Savara Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-04T06:29:38.000Z - 7 months ago

Savara Hit with Class Action Over Molbreevi Misrepresentations

Oct 31, 2025, 4:05 PM EDT - 7 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 29, 2025, 9:43 PM EDT - 7 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 4:07 PM EDT - 7 months ago

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 7 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 17, 2025, 8:05 AM EDT - 7 months ago

Savara Announces Chief Medical Officer (CMO) Transition

Oct 2, 2025, 4:05 PM EDT - 8 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Sep 29, 2025, 2:00 AM EDT - 8 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

BioGem May. 24 at 11:49 PM

0 · Reply

BaronVonGrimm May. 20 at 10:37 PM

$SVRA will rest $11-$16

0 · Reply

Zeffanator2 May. 20 at 6:28 PM

$SVRA We will be just fine…..

2 · Reply

Spacemonkey1 May. 20 at 1:07 PM

$SVRA hard to argue this data doesn’t significantly reinforce likelihood of FDA approval. They love biomarkers and functional improvements. They got both.

0 · Reply

DARKP00L May. 20 at 12:55 PM

0 · Reply

ckruel May. 19 at 8:31 PM

$SVRA https://finance.yahoo.com/sectors/healthcare/articles/savara-presented-long-term-efficacy-181500105.html

1 · Reply

biovaluable May. 19 at 2:13 PM

$SVRA major.amendants? The end?

0 · Reply

Richterscale May. 18 at 7:51 PM

$SVRA why is this getting hammered on? This is good news

2 · Reply

Richterscale May. 18 at 7:21 PM

$SVRA https://www.businesswire.com/news/home/20260518925976/en/

0 · Reply

Monkey7779192 May. 14 at 5:22 PM

$SVRA First time pdufa?

0 · Reply

ckruel May. 13 at 9:24 PM

$SVRA new price targets . Check out SVRA $5.27 on TipRanks https://tipranks.onelink.me/WJho/9r6i9akr

1 · Reply

BioSpecialOne May. 12 at 12:58 PM

$SVRA PDUFA pushed to Nov 22 because of a "Major Amendment". Management claims no safety or efficacy issues were cited, but major amendments usually mean the original NDA had holes. The balance sheet is a fortress with zero dilution risk, but holding this now means locking up capital in dead money for 6 months. Is anyone actually playing the ATS data presentation this month as a real catalyst, or is it just noise to distract from the delay? Trying to see the bull case for deploying capital now instead of waiting for a clean Q4 entry.

1 · Reply

Richterscale May. 11 at 7:56 PM

$SVRA I sold on the $.12 pump this morning. Loooks like I actually made a good decision I still expect a little run up to the FL conference.

0 · Reply

Merlintrader May. 9 at 4:27 PM

$UNCY Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist and Savara. $PTGX $SVRA) https://www.merlintrader.com/three-2026-fda-decisions/

0 · Reply

Richterscale May. 7 at 7:08 PM

$SVRA We need some news

1 · Reply

Spacemonkey1 May. 4 at 5:09 PM

$SVRA upcoming oral presentation: Oral Presentation. So, we know it improves exercise duration and distance, which is huge because FDA likes to see functional improvement. Title: Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial Mini Symposium: B95 – Fibrosis, Cough, and Inflammation: Treatment Strategies in ILD Abstract Number: 9296 Date/Time: Monday, May 18, 2026, 2:51 - 3:03 PM EDT

0 · Reply

Richterscale Apr. 30 at 7:28 PM

$SVRA news?

2 · Reply

PennOhio Apr. 29 at 3:29 PM

$SVRA I don’t take way that at all. The FDA asked for more data and that triggered further review per guidance/proceed.

1 · Reply

OfficialStocktwitsUser Apr. 29 at 2:42 AM

$SVRA RSI: 31.30, MACD: -0.1010 Vol: 0.34, MA20: 5.55, MA50: 5.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Stormvyre Apr. 25 at 6:26 AM

$SVRA 👀

0 · Reply

Danboo Apr. 24 at 9:13 PM

$SVRA Surfactant dysfunction is a hallmark disease element of aPaP which the Savara investigational drug is designed to address. Similarly, surfactant dysfunction is a hallmark element of COPD. FDA approval of the Savara drug opens the door to investigational expansion or off-label therapeutic expansion into the COPD disease population. Medinfo

0 · Reply

Danboo Apr. 24 at 8:47 PM

$SVRA When Savara first went public there was a massive dilution of then Savara stock into new shares. The current proxy statement now calls for approval of expanding share authorization from 300 M to 600M. This suggests that upon FDA approval Savara management may authorize a stock split to restore partially or entirely pre dilution shares to investors. Medinfo

2 · Reply

Market Cap	1.03B
Revenue (ttm)	0.00
Net Income (ttm)	-118.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.17

Volume	668,200
Avg Vol	1,550,022
Day's Range	N/A - N/A
Shares Out	204.93M
Stochastic %K	45%
Beta	0.28
Analysts	Strong Sell
Price Target	$10.94